Main menu
Latest Filings
Issuer Activity
| Insider Overview :: Valeant Pharmaceuticals International, Inc. (T:VRX) | [?] |
| Business Focus: Pharmaceuticals | |
| This company is also listed in the United States as VRX on the NYSE. Click here to see if there are any SEC insider filings on insidertracking.com. | |
|
|
| |
| Latest 10 SEDI filings (by transaction date) for VRX within the last 6 months | [?] |
 Amended Filing | |
| As of 11:59pm ET May 17th, 2013 | |||||||
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | # or value acquired or disposed of | Price |
| Apr 23/13 | Apr 20/13 | Kornwasser, Laizer | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 2,000 | |
| Apr 23/13 | Apr 20/13 | Schiller, Howard | Direct Ownership | Common Shares | 57 - Exercise of rights | 4,461 | |
| Apr 23/13 | Apr 20/13 | Schiller, Howard | Direct Ownership | Rights Restricted Share Units (RSUs) | 57 - Exercise of rights | -9,266 | |
| Apr 3/13 | Mar 31/13 | Provencio, Norma Ann | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 466 | |
| Apr 3/13 | Mar 31/13 | Melas-Kyriazi, Theo | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 341 | |
| Apr 3/13 | Mar 31/13 | Farmer, Ron | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 324 | |
| Mar 22/13 | Mar 15/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -287,268 | |
| Mar 22/13 | Mar 15/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 287,268 | |
| Mar 22/13 | Mar 14/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -212,983 | |
| Mar 22/13 | Mar 14/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 212,983 | |
| This company is also listed in the United States as VRX on the NYSE. Click here to see if there are any SEC insider filings on insidertracking.com. Sign up for an account or login above to see all SEDI filings within the past 6 months. | |||||||
| Latest 10 SEDI filings (by filing date) for VRX within the last 6 months | [?] |
| Amended Filing | |
| As of 11:59pm ET May 17th, 2013 | |||||||
| Filing Date | Transaction Date | Insider Name | Ownership Type | Securities | Nature of transaction | # or value acquired or disposed of | Price |
| Apr 23/13 | Apr 20/13 | Kornwasser, Laizer | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 2,000 | |
| Apr 23/13 | Apr 20/13 | Schiller, Howard | Direct Ownership | Common Shares | 57 - Exercise of rights | 4,461 | |
| Apr 23/13 | Apr 20/13 | Schiller, Howard | Direct Ownership | Rights Restricted Share Units (RSUs) | 57 - Exercise of rights | -9,266 | |
| Apr 3/13 | Mar 31/13 | Provencio, Norma Ann | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 466 | |
| Apr 3/13 | Mar 31/13 | Melas-Kyriazi, Theo | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 341 | |
| Apr 3/13 | Mar 31/13 | Farmer, Ron | Direct Ownership | Rights Restricted Share Units (RSUs) | 56 - Grant of rights | 324 | |
| Mar 22/13 | Mar 15/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -287,268 | |
| Mar 22/13 | Mar 15/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 287,268 | |
| Mar 22/13 | Mar 14/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | -212,983 | |
| Mar 22/13 | Mar 14/13 | Valeant Pharmaceuticals International, Inc. | Direct Ownership | Common Shares | 38 - Redemption, retraction, cancellation, repurchase | 212,983 | |
| This company is also listed in the United States as VRX on the NYSE. Click here to see if there are any SEC insider filings on insidertracking.com. Sign up for an account or login above to see all SEDI filings within the past 6 months. | |||||||
| Sign up for an account or login above to see the past 6 months of SEDI filings sorted by insider. |
| Markers (TSX Insider Summaries) for VRX on May 17, 2013 | [?] |
 Marker Correction | |
| Trading Date | Ticker | Insider Volume | Average Buy Price | Average Sell Price | ||
| Buy | Sell | Net | ||||
| May 17/13 |  VRX | 450 | -450 | $78.610 | ||
| To view other marker data and corrections for the past week, sign up for an account or log in above. To view more historical data and corrections, sign up for an account at inkresearch.com | ||||||
| Sector: Healthcare | Industry: Pharmaceuticals |
| Key People | ||
| J. Michael Pearson Chairman of the Board, Chief Executive Officer | Howard B. Schiller Chief Financial Officer, Executive Vice President, Director | Robert R. Chai-Onn Executive Vice President, General Counsel, Corporate Secretary and Corporate Business Development |
| Laizer D. Kornwasser Executive Vice President, Company Group Chairman | Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer | Ryan Weldon Executive Vice President, Company Group Chairman | Susan T. Hall Senior Vice President, Global Head - Research and Development |
| Company Contact | |
| Address: | 2150 St. Elzear Blvd., West Laval MONTREAL QC H7L 4A8 |
| Tel: | 1-949-4616002 |
| Website: | www.valeant.com |
| IR: | phx.corporate-ir.net/phoenix.zhtml?c=90887&p=irol-irhome |
| Business Overview |
| Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company operates in five business segments: U.S. Neurology and Other, U.S. Dermatology, Canada and Australia, Branded Generics - Europe and Branded Generics -Latin America. Within its U.S. Dermatology segment and Branded Generic - Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication. On March 12, 2012, it acquired a 19.9% minority equity investment in Pele Nova Biotecnologia S.A. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc. |
| Competitors with Recent Insider Filings |
| Paladin Labs (T:PLB) |
| Sophiris Bio (T:SHS) |
| Cipher Pharmaceuticals (T:DND) |
 Valeant Pharmaceuticals International, Inc. Insider Report Only $20.00  |